Back to Journals » ClinicoEconomics and Outcomes Research » Volume 10

Epidemiology, associated burden, and current clinical practice for the diagnosis and management of Alzheimer’s disease in Japan

Authors Montgomery W, Ueda K, Jorgensen M, Stathis S, Cheng Y, Nakamura T

Received 19 July 2017

Accepted for publication 2 November 2017

Published 28 December 2017 Volume 2018:10 Pages 13—28

DOI https://doi.org/10.2147/CEOR.S146788

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Amy Norman

Peer reviewer comments 3

Editor who approved publication: Professor Giorgio Lorenzo Colombo


William Montgomery,1 Kaname Ueda,2 Margaret Jorgensen,3 Shari Stathis,3 Yuanyuan Cheng,3 Tomomi Nakamura2

1Global Patient Outcomes & Real World Evidence, Eli Lilly Australia, Sydney, NSW, Australia; 2Medical Development Unit-Japan, Eli Lilly Japan KK, Kobe, Japan; 3Health Technology Analysts, Lilyfield, NSW, Australia

Abstract: The burden of dementia in Japan is large and growing. With the world’s fastest aging population, it is estimated that one in five elderly people will be living with dementia in Japan by 2025. The most common form of dementia is Alzheimer’s disease (AD), accounting for around two-thirds of dementia cases. A systematic review was conducted to examine the epidemiology and associated burden of AD in Japan and to identify how AD is diagnosed and managed in Japan. English and Japanese language databases were searched for articles published between January 2000 and November 2015. Relevant Japanese sources, clinical practice guideline registers, and reference lists were also searched. Systematic reviews and cohort and case–control studies were eligible for inclusion, with a total of 60 studies included. The most recent national survey conducted in six regions of Japan reported the mean prevalence of dementia in people aged ≥65 years to be 15.75% (95% CI: 12.4, 22.2%), which is much higher than the previous estimated rate of 10% in 2010. AD was confirmed as the predominant type of dementia, accounting for 65.8% of all cases. Advancing age and low education were the most consistently reported risk factors for AD dementia. Japanese guidelines for the management of dementia were released in 2010 providing specific guidance for AD about clinical signs, image findings, biochemical markers, and treatment approaches. Pharmacotherapies and non-pharmacotherapies to relieve cognitive symptoms were introduced, as were recommendations to achieve better patient care. No studies reporting treatment patterns were identified. Due to population aging and growing awareness of AD in Japan, health care expenditure and associated burden are expected to soar. This review highlights the importance of early detection, diagnosis, and treatment of AD as strategies to minimize the impact of AD on society in Japan.

Keywords: dementia, risk factors, treatment patterns, systematic review

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]